AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...